AbbVie's Technivie approved for HCV

FDA approved Technivie ombitasvir/paritaprevir/ritonavir from AbbVie Inc. (NYSE:ABBV) in combination with ribavirin to treat non-cirrhotic adults with chronic HCV genotype 4 infection. The regimen is the first interferon-free treatment for the indication in the U.S.

AbbVie spokesperson Jackie Finley told BioCentury Technivie would be available nationwide in late August at a wholesale acquisition cost (WAC) of $76,653 for 12 weeks of treatment, the shortest approved treatment course. ...